A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). (Q39143108)

9 September 2017

A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). (English)

1 reference

9 September 2017

0 references

meningococcal disease

1 reference

7

1 reference

9 September 2017

8

1 reference

9 September 2017

5

Gerd Pluschke

1 reference

9 September 2017

Oliver Koeberling

1

1 reference

9 September 2017

Emma Ispasanie

2

1 reference

9 September 2017

Julia Hauser

3

1 reference

9 September 2017

Omar Rossi

4

1 reference

9 September 2017

Dominique A Caugant

6

1 reference

9 September 2017

language of work or name

English

0 references

publication date

3 April 2014

1 reference

9 September 2017

1 reference

9 September 2017

32

1 reference

9 September 2017

2688-2695

1 reference

9 September 2017

23

1 reference

The changing and dynamic epidemiology of meningococcal disease

9 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Increase in Neisseria meningitidis serogroup W135, Niger, 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

High yield production process for Shigella outer membrane particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

The modular architecture of meningococcal factor H-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Lack of antigenic diversification of major outer membrane proteins during clonal waves of Neisseria meningitidis serogroup A colonization and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Improved methods for producing outer membrane vesicles in Gram-negative bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Structure of the OmpA-like domain of RmpM from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Emergence of W135 meningococcal meningitis in Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Serogroup W135 meningococcal meningitis, Northern Cameroon, 2007-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.068

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.03.068

1 reference

9 September 2017

1 reference